Research programme: cystic fibrosis therapeutics - CBR/IVAX
Latest Information Update: 07 Aug 2007
At a glance
- Originator CBR Laboratories
- Developer CBR Laboratories; IVAX Corporation
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
- 20 Jul 2000 Preclinical development for Cystic fibrosis in USA (Inhalation)